BPC-157
BPC-157 is a synthetic peptide associated with tissue repair and gut-healing claims, but it remains one of the most watched restricted peptides in U.S. compounding.
Current status
Restricted
Tissue repair and gut healing, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Market watchers continue to treat BPC-157 as a leading candidate for future FDA reconsideration, but no formal change has landed.
Primary Use
Tissue repair and gut healing
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: Placed on FDA Category 2 lists for compounding restrictions..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when BPC-157 status changes
State-specific notes
California
Dispensing posture is especially conservative.
Texas
Compounding partners typically avoid it entirely.